ctDNA Testing May Provide Sufficient Accuracy For Widespread Adoption In Routine Clinical Practice To Identify Patients With Breast Cancer Suitable For Targeted Therapies
Cancer Network (9/17, Slater) reports researchers found in a phase 2a trial “that circulating tumor DNA (ctDNA) testing provides sufficient accuracy for widespread adoption in routine clinical practice to identify patients with breast cancer who are suitable for licensed targeted therapies, with the potential of efficient and rapid screening for clinical trials as well.” The findings (PDF) were published in The Lancet Oncology.